314 related articles for article (PubMed ID: 37900041)
21. Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.
Hajissa K; Islam MA; Hassan SA; Zaidah AR; Ismail N; Mohamed Z
Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742506
[TBL] [Abstract][Full Text] [Related]
22. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.
Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A
Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign.
Meyers E; De Rop L; Deschepper E; Duysburgh E; De Burghgraeve T; Van Ngoc P; Digregorio M; Delogne S; Coen A; De Clercq N; Buret L; Coenen S; De Sutter A; Scholtes B; Verbakel JY; Cools P; Heytens S
Eur J Gen Pract; 2023 Dec; 29(2):2149732. PubMed ID: 36440533
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials.
Yang ZR; Jiang YW; Li FX; Liu D; Lin TF; Zhao ZY; Wei C; Jin QY; Li XM; Jia YX; Zhu FC; Yang ZY; Sha F; Feng ZJ; Tang JL
Lancet Microbe; 2023 Apr; 4(4):e236-e246. PubMed ID: 36868258
[TBL] [Abstract][Full Text] [Related]
25. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
COVID-19 Cumulative Infection Collaborators
Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
[TBL] [Abstract][Full Text] [Related]
26. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z
BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390
[TBL] [Abstract][Full Text] [Related]
27. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 vaccine coverage and factors associated with vaccine uptake among 23 247 adults with a recent history of homelessness in Ontario, Canada: a population-based cohort study.
Shariff SZ; Richard L; Hwang SW; Kwong JC; Forchuk C; Dosani N; Booth R
Lancet Public Health; 2022 Apr; 7(4):e366-e377. PubMed ID: 35278362
[TBL] [Abstract][Full Text] [Related]
29. Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.
Raqib R; Sarker P; Akhtar E; Nurul Huda TM; Haq MA; Roy AK; Hosen MB; Haque F; Chowdhury MR; Reidpath DD; Emdadul Hoque DM; Islam Z; Ahmed S; Ahmed T; Tofail F; Razzaque A
PLoS One; 2022; 17(5):e0268093. PubMed ID: 35604947
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of SARS-CoV-2 antibodies among nurses: A systematic review and meta-analysis.
He S; Hecimovic A; Matijasevic V; Mai HT; Heslop L; Foster J; Alexander KE; Pal N; Alexandrou E; Davidson PM; Frost SA
J Clin Nurs; 2022 Jun; 31(11-12):1557-1569. PubMed ID: 34570947
[TBL] [Abstract][Full Text] [Related]
31. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J
Front Public Health; 2023; 11():1165611. PubMed ID: 37325336
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
36. Seroprevalence of SARS-CoV-2 antibodies among homeless people living rough, in shelters and squats: A large population-based study in France.
Loubiere S; Monfardini E; Allaria C; Mosnier M; Allibert A; Ninove L; Bosetti T; Farnarier C; Hamouda I; Auquier P; Mosnier E; Tinland A
PLoS One; 2021; 16(9):e0255498. PubMed ID: 34525096
[TBL] [Abstract][Full Text] [Related]
37. Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021.
Busch MP; Stramer SL; Stone M; Yu EA; Grebe E; Notari E; Saa P; Ferg R; Manrique IM; Weil N; Fink RV; Levy ME; Green V; Cyrus S; Williamson PC; Haynes J; Groves J; Krysztof D; Custer B; Kleinman S; Biggerstaff BJ; Opsomer JD; Jones JM
Clin Infect Dis; 2022 Oct; 75(Suppl 2):S254-S263. PubMed ID: 35684973
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis.
Rahmani K; Shavaleh R; Forouhi M; Disfani HF; Kamandi M; Oskooi RK; Foogerdi M; Soltani M; Rahchamani M; Mohaddespour M; Dianatinasab M
Front Public Health; 2022; 10():873596. PubMed ID: 36091533
[TBL] [Abstract][Full Text] [Related]
39. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
[TBL] [Abstract][Full Text] [Related]
40. Importance of occupation for SARS-CoV-2 seroprevalence and COVID-19 vaccination among correctional workers in Quebec, Canada: A cross-sectional study.
Kronfli N; Dussault C; Maheu-Giroux M; Halavrezos A; Chalifoux S; Park H; Balso LD; Cheng MP; Cox J
Front Public Health; 2022; 10():1021871. PubMed ID: 36438247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
